This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration (FDA) has delayed the full approval of Novavaxs COVID-19 vaccine. The decision had been expected by April 1, but the agency now says it needs more information before moving forward.The. FRIDAY, April 4, 2025 -- The U.S.
The COVID-19 pandemic brought mRNA to global prominence by developing highly effective vaccines by Moderna and Pfizer-BioNTech. However, mRNA technology has introduced new possibilities, particularly in developing personalized cancer vaccines and combination therapies. Another challenge is the potential for unintended immune responses.
In the realm of vaccine development, mega trials — studies enrolling 5,000 subjects or more — have been instrumental in the fight against many pathogens, including influenza, rotavirus, malaria, RSV and most recently in the rapid development of vaccines against COVID-19.
Mechanistic modeling can be used to describe the time course of vaccine-induced humoral immunity and to identify key biological drivers in antibody production. We utilized a six-compartment mechanistic model to describe a 20-week time course of humoral immune responses in 56 non-human primates (NHPs) elicited by vaccination with Ad26.COV2.S
Professor Alexander Chuchalin has quit the Russian Health Ministry’s ethics council due to the quick approval process for the country’s coronavirus vaccine. Many countries have criticised Russia pursuit for a COVID-19 cure, which has skipped Phase 3 trials before giving the vaccine regulatory approval. Safety always comes first.
Vaccines for COVID-19 are the focus of the moment – politically and scientifically speaking. Scientifically, there was the big news that a vaccine trial had experienced a serious adverse event bringing a pause to bear in its continuation, likely throwing further cold water on the political side of the equation.
Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.
3, 2020 — All Americans who get a COVID-19 vaccine will get a vaccination card, officials say. associate director of the Immunization Action Coalition, which supports frontline workers who will administer COVID-19 vaccinations, CNN reported. Further Support and Information on COVID-19. THURSDAY, Dec. CNN Article.
The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines. Secondary objectives are to describe immune responses produced by each of the vaccines.
8, 2021 — As Americans await their COVID-19 shot, a new study of a different vaccine shows the power of Facebook posts in fueling “anti-vax” resistance to immunization. The study included more than 10 years of public Facebook posts on the human papillomavirus (HPV) vaccine. 8 in the journal Vaccine.
Canada Approves Pfizer COVID-19 Vaccine. 9, 2020 — The Pfizer COVID-19 vaccine has been approved by Canada’s health agency and the first Canadians could start receiving it next week. Britain approved the vaccine earlier, but it was an emergency approval largely based on the Pfizer analysis. WEDNESDAY, Dec.
Third COVID-19 Vaccine Shows Effectiveness. 23, 2020 — On Monday, AstraZeneca announced that late-stage clinical trials of its COVID-19 vaccine showed it to be 70.4 The AstraZeneca vaccine becomes the third vaccine to show good effectiveness, following on the heels of promising data on vaccines from Pfizer and Moderna.
We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine. Out of an abundance of caution, the CDC and FDA have recommended a pause in the use of our vaccine. cases out of more than 6.8
Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization. More Information.
Marshals to Protect COVID-19 Vaccines. 11, 2020 — COVID-19 vaccines will be protected by U.S. Food and Drug Administration is expected to quickly give emergency authorization to the Pfizer COVID-19 vaccine, which would be followed by an undertaking to distribute 3 million doses of the vaccine nationwide, CBS News reported.
11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. ” Can the vaccines make you sick? How safe and effective are the vaccines?
The Fact Sheet for Healthcare Providers Administering Vaccine now reflects the revision of the authorized use of the Janssen COVID-19 Vaccine and includes a warning statement at the beginning of the fact sheet for prominence which summarizes information on the risk for TTS.
Moderna Vaccine Shows 94.5 announced on Monday that early results show its COVID-19 vaccine is 94.5 The researchers behind the vaccine said the results were far better than they had hoped. The Moderna vaccine results were analyzed by an independent data safety monitoring board, appointed by the U.S. More Information.
Indigenous Communities Start Receiving COVID-19 Vaccines. 18, 2020 — Indigenous communities in the United States have started receiving COVID-19 vaccines from federal and state agencies. Other tribes will receive vaccine deliveries through state health agencies, the AP reported. Further Support and Information on COVID-19.
public report that they would definitely or probably get a COVID-19 vaccine, marking an increase from 63 percent in September, according to the ongoing research project, the KFF COVID-19 Vaccine Monitor. The KFF COVID-19 Vaccine Monitor used a combination of surveys and focus groups to track the U.S. More Information.
.
AstraZeneca has confirmed that clinical trials assessing its Oxford University partnered coronavirus vaccine AZD1222 have resumed in the UK, following a green light by the Medicines Health Regulatory Authority (MHRA). AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech.
Source link.
Insights from Optimity app user survey finds that 43% believe the COVID-19 vaccine should be mandatory, while 53% believe that Canadians should have a choice of which vaccine to receive. Among the topics addressed in the survey was consumer concern about possible long-term and short-term side effects from the vaccine.
COVID-19 Vaccine Trial Enrolls 30,000. 22, 2020 — The first company to start a phase 3 trial of a COVID-19 vaccine reached its target of enrolling 30,000 participants, CNN reported Thursday. Half of the participants were given the vaccine and half received a placebo. That would show the vaccine is 75 percent effective.
AHA: Young Adults With CVD Have Low Flu Vaccination Rates. 10, 2020 — Many young adults with cardiovascular disease (CVD) do not receive influenza vaccination, according to a study presented at the American Heart Association Scientific Sessions 2020, held virtually from Nov. More Information. Professional. TUESDAY, Nov.
FDA Review Finds Pfizer COVID-19 Vaccine Effective After First Dose. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee suggest that Pfizer’s two-dose COVID-19 vaccine works well protecting recipients against COVID-19. Further Support and Information on COVID-19. Professional.
Moderna has revealed that it was impacted by last week’s cyberattack on the European Medicines Agency (EMA), during which hackers compromised agency computer systems and accessed vaccine regulatory submission documents for Pfizer/BioNTech’s and Moderna’s COVID-19 vaccines. biotech firms ( DID , July 22 ).
ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies. The ACAAI COVID-19 Vaccine Task Force issued the guidance related to the risk for an allergic reaction with the Pfizer-BioNTech COVID-19 vaccine that was given emergency use authorization by the U.S. ” More Information. Professional.
9, 2021 — A task force of allergists and immunologists recommends those administering the COVID-19 vaccine ask patients some key questions beforehand. If the answer is yes, the individual should be referred to a board-certified allergist for evaluation before getting the COVID-19 vaccination, ACAAI said in a news release.
Fauci ‘Cautiously Optimistic’ for COVID-19 Vaccine by Year’s End. the leading infectious disease expert in the United States, said on Wednesday he is “cautiously optimistic” that a COVID-19 vaccine will be ready by year’s end. Multiple studies are testing three vaccine approaches, Fauci said.
FDA Advisory Committee OKs Pfizer-BioNTech COVID-19 Vaccine. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee today voted to recommend emergency use authorization (EUA) of the COVID-19 vaccine manufactured by Pfizer and BioNTech. Further Support and Information on COVID-19.
government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. government with 500 million doses of the companies’ COVID-19 vaccine for donation to the world’s poorest nations. government in the fight against this pandemic, we are proud of the impact of vaccination efforts across the country.
Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 10 to discuss the request for emergency use authorization (EUA) of a COVID-19 vaccine from Pfizer, Inc. November 20, 2020 — The U.S. in partnership with BioNTech Manufacturing GmbH.
This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group. COMIRNATY was the first COVID-19 vaccine to receive authorization in the EU and is the first to have its CMA extended to adolescents. g doses of the COVID-19 vaccine.
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. mRNA vaccines include the Pfizer-BioNTech Comirnaty vaccine and the Moderna Spikevax vaccine.
EU Regulator Approves Oxford-AstraZeneca COVID-19 Vaccine. 29, 2021 — European Union regulators have authorized the AstraZeneca COVID-19 vaccine for use in adults, CBS News reported Friday. The move comes after the European Medicines Agency has been criticized for not moving fast enough to vaccinate its population.
7, 2021 — The National Football League is asking teams to use their stadiums as places people can go to get vaccinated for COVID-19, CBS News reported Wednesday. ” Using arenas for vaccinations is not a new idea. . ” Using arenas for vaccinations is not a new idea. Further Support and Information on COVID-19.
Two-Thirds of Lupus Patients Likely to Take COVID-19 Vaccine. 6, 2021 — Two-thirds of people with lupus are willing to receive a COVID-19 vaccine, according to the results of a survey released by the Lupus Research Alliance. Hispanic respondents are most likely (34 percent) to say they are undecided about taking the vaccine.
The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.
Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. .–( BUSINESS WIRE )– Moderna, Inc.,
Anaphylaxis Cases Reported Per Million COVID-19 Moderna Vaccine Shots. cases per million Moderna COVID-19 vaccine doses administered as of Jan. percent) adverse events after receipt of the Moderna COVID-19 vaccine were submitted to the Vaccine Adverse Event Reporting System as of Jan. Professional. MONDAY, Jan.
COVID-19 Vaccine Caution Issued by U.K. 9, 2020 — People with a “significant history” of allergic reactions should not receive the new Pfizer-BioNTech COVID-19 vaccine, U.K. mass vaccination program, the Associated Press reported. mass vaccination program, the Associated Press reported. Professional.
No Pfizer COVID-19 Vaccine Expected Before Election. 19, 2020 — Pfizer will not apply for emergency authorization of its COVID-19 vaccine before the third week in November, the company’s chief executive said in a statement posted to the Pfizer website on Friday. Further Support and Information on COVID-19.
company developing UB-612 a multitope peptide-based vaccine to fight COVID-19, today announced an exclusive agreement with Aurobindo Pharma to expand its global development and commercialization of UB-612 to India and the United Nations Children’s Fund (UNICEF) agency. billion, to deliver the vaccine in multiple countries.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content